

# SAFETY DATA SHEET

according to the Hazardous Products Regulations



## Furosemide Injection Formulation

|         |                |              |                                 |
|---------|----------------|--------------|---------------------------------|
| Version | Revision Date: | SDS Number:  | Date of last issue: 04/04/2023  |
| 3.9     | 09/30/2023     | 632199-00016 | Date of first issue: 05/03/2016 |

### SECTION 1. IDENTIFICATION

Product name : Furosemide Injection Formulation  
Other means of identification : No data available

#### Manufacturer or supplier's details

Company name of supplier : Merck & Co., Inc  
Address : 37 McCarville Street  
Charlottetown, PE C1E 2A7  
Telephone : 908-740-4000  
Emergency telephone : 1-908-423-6000  
E-mail address : EHSDATASTEWARD@merck.com

#### Recommended use of the chemical and restrictions on use

Recommended use : Veterinary product  
Restrictions on use : Not applicable

### SECTION 2. HAZARDS IDENTIFICATION

#### GHS classification in accordance with the Hazardous Products Regulations

Specific target organ toxicity : Category 1 (Kidney, Liver)  
- repeated exposure

#### GHS label elements

Hazard pictograms :



Signal Word : Danger

Hazard Statements : H372 Causes damage to organs (Kidney, Liver) through prolonged or repeated exposure.

Precautionary Statements :  
**Prevention:**  
P260 Do not breathe mist or vapors.  
P264 Wash skin thoroughly after handling.  
P270 Do not eat, drink or smoke when using this product.  
**Response:**  
P314 Get medical attention if you feel unwell.  
**Disposal:**  
P501 Dispose of contents and container to an approved waste disposal plant.

#### Other hazards

None known.

# SAFETY DATA SHEET

according to the Hazardous Products Regulations



## Furosemide Injection Formulation

Version 3.9      Revision Date: 09/30/2023      SDS Number: 632199-00016      Date of last issue: 04/04/2023  
Date of first issue: 05/03/2016

### SECTION 3. COMPOSITION/INFORMATION ON INGREDIENTS

Substance / Mixture : Mixture

#### Components

| Chemical name | Common Name/Synonym | CAS-No. | Concentration (% w/w) |
|---------------|---------------------|---------|-----------------------|
| Furosemide    | No data available   | 54-31-9 | $\geq 5 - < 10$ *     |

\* Actual concentration or concentration range is withheld as a trade secret

### SECTION 4. FIRST AID MEASURES

General advice : In the case of accident or if you feel unwell, seek medical advice immediately.  
When symptoms persist or in all cases of doubt seek medical advice.

If inhaled : If inhaled, remove to fresh air.  
Get medical attention if symptoms occur.

In case of skin contact : In case of contact, immediately flush skin with soap and plenty of water.  
Get medical attention if symptoms occur.

In case of eye contact : Flush eyes with water as a precaution.  
Get medical attention if irritation develops and persists.

If swallowed : If swallowed, DO NOT induce vomiting.  
Get medical attention if symptoms occur.  
Rinse mouth thoroughly with water.

Most important symptoms and effects, both acute and delayed : Causes damage to organs through prolonged or repeated exposure.

Protection of first-aiders : First Aid responders should pay attention to self-protection, and use the recommended personal protective equipment when the potential for exposure exists (see section 8).

Notes to physician : Treat symptomatically and supportively.

### SECTION 5. FIRE-FIGHTING MEASURES

Suitable extinguishing media : Water spray  
Alcohol-resistant foam  
Carbon dioxide (CO<sub>2</sub>)  
Dry chemical

Unsuitable extinguishing media : None known.

Specific hazards during fire fighting : Exposure to combustion products may be a hazard to health.

Hazardous combustion products : Nitrogen oxides (NO<sub>x</sub>)  
Carbon oxides  
Sulfur oxides  
Chlorine compounds

Specific extinguishing methods : Use extinguishing measures that are appropriate to local circumstances and the surrounding environment.

# SAFETY DATA SHEET

according to the Hazardous Products Regulations



## Furosemide Injection Formulation

|         |                |              |                                 |
|---------|----------------|--------------|---------------------------------|
| Version | Revision Date: | SDS Number:  | Date of last issue: 04/04/2023  |
| 3.9     | 09/30/2023     | 632199-00016 | Date of first issue: 05/03/2016 |

Use water spray to cool unopened containers.  
Remove undamaged containers from fire area if it is safe to do so.  
Evacuate area.  
Special protective equipment : In the event of fire, wear self-contained breathing apparatus.  
for fire-fighters Use personal protective equipment.

### SECTION 6. ACCIDENTAL RELEASE MEASURES

Personal precautions, protective equipment and emergency procedures : Use personal protective equipment.  
Follow safe handling advice (see section 7) and personal protective equipment recommendations (see section 8).

Environmental precautions : Avoid release to the environment.  
Prevent further leakage or spillage if safe to do so.  
Prevent spreading over a wide area (e.g., by containment or oil barriers).  
Retain and dispose of contaminated wash water.  
Local authorities should be advised if significant spillages cannot be contained.

Methods and materials for containment and cleaning up : Soak up with inert absorbent material.  
For large spills, provide diking or other appropriate containment to keep material from spreading. If diked material can be pumped, store recovered material in appropriate container.  
Clean up remaining materials from spill with suitable absorbent.  
Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to determine which regulations are applicable.  
Sections 13 and 15 of this SDS provide information regarding certain local or national requirements.

### SECTION 7. HANDLING AND STORAGE

Technical measures : See Engineering measures under EXPOSURE CONTROLS/PERSONAL PROTECTION section.

Local/Total ventilation : Use only with adequate ventilation.

Advice on safe handling : Do not breathe mist or vapors.  
Do not swallow.  
Avoid contact with eyes.  
Avoid prolonged or repeated contact with skin.  
Wash skin thoroughly after handling.  
Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure assessment  
Do not eat, drink or smoke when using this product.  
Take care to prevent spills, waste and minimize release to the environment.

Conditions for safe storage : Keep in properly labeled containers.  
Store in accordance with the particular national regulations.

# SAFETY DATA SHEET

according to the Hazardous Products Regulations



## Furosemide Injection Formulation

Version 3.9      Revision Date: 09/30/2023      SDS Number: 632199-00016      Date of last issue: 04/04/2023  
Date of first issue: 05/03/2016

Materials to avoid : Do not store with the following product types:  
Strong oxidizing agents  
Self-reactive substances and mixtures  
Organic peroxides  
Explosives  
Gases

### SECTION 8. EXPOSURE CONTROLS/PERSONAL PROTECTION

#### Ingredients with workplace control parameters

| Components | CAS-No. | Value type<br>(Form of exposure) | Control parameters / Permissible concentration | Basis    |
|------------|---------|----------------------------------|--|----------|
| Furosemide | 54-31-9 | TWA                              | 200 µg/m <sup>3</sup>                          | Internal |
|            |         | TWA                              | OEB 2 (>=100 - 1000 µg/m <sup>3</sup> )        | Internal |

**Engineering measures** : Use appropriate engineering controls and manufacturing technologies to control airborne concentrations (e.g., drip-less quick connections).  
All engineering controls should be implemented by facility design and operated in accordance with GMP principles to protect products, workers, and the environment.  
Laboratory operations do not require special containment.

#### Personal protective equipment

**Respiratory protection** : If adequate local exhaust ventilation is not available or exposure assessment demonstrates exposures outside the recommended guidelines, use respiratory protection.

**Filter type** : Particulates type

**Hand protection** : Chemical-resistant gloves

**Material** : Chemical-resistant gloves

**Eye protection** : Wear safety glasses with side shields or goggles.  
If the work environment or activity involves dusty conditions, mists or aerosols, wear the appropriate goggles.  
Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or aerosols.

**Skin and body protection** : Work uniform or laboratory coat.

**Hygiene measures** : If exposure to chemical is likely during typical use, provide eye flushing systems and safety showers close to the working place.  
When using do not eat, drink or smoke.  
Wash contaminated clothing before re-use.  
The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the use of administrative controls.

### SECTION 9. PHYSICAL AND CHEMICAL PROPERTIES

# SAFETY DATA SHEET

according to the Hazardous Products Regulations



## Furosemide Injection Formulation

|         |                |              |                                 |
|---------|----------------|--------------|---------------------------------|
| Version | Revision Date: | SDS Number:  | Date of last issue: 04/04/2023  |
| 3.9     | 09/30/2023     | 632199-00016 | Date of first issue: 05/03/2016 |

---

|  |   |  |
|--|---|--|
| Appearance                                       | : | Aqueous solution   |
| Color  | : | yellow   |
| Odor   | : | No data available  |
| Odor Threshold                                   | : | No data available  |
| pH   | : | No data available  |
| Melting point/freezing point                     | : | No data available  |
| Initial boiling point and boiling range          | : | No data available  |
| Flash point                                      | : | No data available  |
| Evaporation rate                                 | : | No data available  |
| Flammability (solid, gas)                        | : | Not applicable   |
| Flammability (liquids)                           | : | No data available  |
| Upper explosion limit / Upper flammability limit | : | No data available  |
| Lower explosion limit / Lower flammability limit | : | No data available  |
| Vapor pressure                                   | : | No data available  |
| Relative vapor density                           | : | No data available  |
| Relative density                                 | : | No data available  |
| Density  | : | No data available  |
| Solubility(ies)                                  |   |  |
| Water solubility                                 | : | No data available  |
| Partition coefficient: n-octanol/water           | : | No data available  |
| Autoignition temperature                         | : | No data available  |
| Decomposition temperature                        | : | No data available  |
| Viscosity  |   |  |
| Viscosity, kinematic                             | : | No data available  |
| Explosive properties                             | : | Not explosive  |
| Oxidizing properties                             | : | The substance or mixture is not classified as oxidizing. |

# SAFETY DATA SHEET

according to the Hazardous Products Regulations



## Furosemide Injection Formulation

|         |                |              |                                 |
|---------|----------------|--------------|---------------------------------|
| Version | Revision Date: | SDS Number:  | Date of last issue: 04/04/2023  |
| 3.9     | 09/30/2023     | 632199-00016 | Date of first issue: 05/03/2016 |

Particle size : Not applicable

### SECTION 10. STABILITY AND REACTIVITY

|                                    |  |
|------------------------------------|--|
| Reactivity                         | : Not classified as a reactivity hazard.         |
| Chemical stability                 | : Stable under normal conditions.                |
| Possibility of hazardous reactions | : Can react with strong oxidizing agents.        |
| Conditions to avoid                | : None known.                                    |
| Incompatible materials             | : Oxidizing agents                               |
| Hazardous decomposition products   | : No hazardous decomposition products are known. |

### SECTION 11. TOXICOLOGICAL INFORMATION

#### Information on likely routes of exposure

Inhalation  
Skin contact  
Ingestion  
Eye contact

#### Acute toxicity

Not classified based on available information.

#### Product:

Acute oral toxicity : Acute toxicity estimate: > 2,000 mg/kg  
Method: Calculation method

#### Components:

##### Furosemide:

|   |  |
|---|--|
| Acute oral toxicity                             | : LD50 (Rat): 2,600 mg/kg                                      |
|   | LD50 (Dog): 2,000 mg/kg  |
|   | LD50 (Rabbit): 800 mg/kg                                       |
| Acute toxicity (other routes of administration) | : LD0 (Humans): 6 - 29 mg/kg<br>Application Route: Intravenous |
|   | LD50 (Rat): 800 mg/kg<br>Application Route: Intravenous        |

#### Skin corrosion/irritation

Not classified based on available information.

#### Serious eye damage/eye irritation

Not classified based on available information.

# SAFETY DATA SHEET

according to the Hazardous Products Regulations



## Furosemide Injection Formulation

|         |                |              |                                 |
|---------|----------------|--------------|---------------------------------|
| Version | Revision Date: | SDS Number:  | Date of last issue: 04/04/2023  |
| 3.9     | 09/30/2023     | 632199-00016 | Date of first issue: 05/03/2016 |

---

### Respiratory or skin sensitization

#### Skin sensitization

Not classified based on available information.

#### Respiratory sensitization

Not classified based on available information.

#### Germ cell mutagenicity

Not classified based on available information.

### Components:

#### Furosemide:

|                       |   |  |
|-----------------------|---|--|
| Genotoxicity in vitro | : | Test Type: Bacterial reverse mutation assay (AMES)<br>Result: negative   |
|                       |   | Test Type: In vitro mammalian cell gene mutation test<br>Test system: mouse lymphoma cells<br>Result: positive   |
|                       |   | Test Type: DNA damage and repair, unscheduled DNA synthesis in mammalian cells (in vitro)<br>Test system: mammalian liver cells<br>Result: negative                            |
|                       |   | Test Type: Chromosome aberration test in vitro<br>Test system: Chinese hamster ovary cells<br>Result: positive   |
|                       |   | Test Type: In vitro sister chromatid exchange assay in mammalian cells<br>Test system: Chinese hamster cells<br>Result: negative   |
| Genotoxicity in vivo  | : | Test Type: Mammalian erythrocyte micronucleus test (in vivo cytogenetic assay)<br>Species: Mouse<br>Application Route: Ingestion<br>Result: negative                           |
|                       |   | Test Type: Mutagenicity (in vivo mammalian bone-marrow cytogenetic test, chromosomal analysis)<br>Species: Chinese hamster<br>Application Route: Ingestion<br>Result: negative |

### Carcinogenicity

Not classified based on available information.

### Components:

#### Furosemide:

|         |   |     |
|---------|---|-----|
| Species | : | Rat |
|---------|---|-----|

# SAFETY DATA SHEET

according to the Hazardous Products Regulations



## Furosemide Injection Formulation

|         |                |              |                                 |
|---------|----------------|--------------|---------------------------------|
| Version | Revision Date: | SDS Number:  | Date of last issue: 04/04/2023  |
| 3.9     | 09/30/2023     | 632199-00016 | Date of first issue: 05/03/2016 |

Application Route : Ingestion  
Exposure time : 104 weeks  
LOAEL : 16 mg/kg body weight  
Result : equivocal

Species : Mouse  
Application Route : Ingestion  
Exposure time : 2 Years  
LOAEL : 91 mg/kg body weight  
Result : positive

### Reproductive toxicity

Not classified based on available information.

### Components:

#### Furosemide:

Effects on fertility : Test Type: One-generation reproduction toxicity study  
Species: Rat  
Application Route: Ingestion  
General Toxicity Parent: NOAEL: 90 mg/kg body weight  
Result: No effects on reproduction parameters.

Test Type: One-generation reproduction toxicity study  
Species: Mouse  
Application Route: Ingestion  
General Toxicity Parent: NOAEL: 200 mg/kg body weight  
Result: No effects on reproduction parameters.

Effects on fetal development : Test Type: Fertility/early embryonic development  
Species: Rat  
Application Route: Ingestion  
General Toxicity Maternal: LOAEL: 50 mg/kg body weight  
Developmental Toxicity: NOAEL: 300 mg/kg body weight  
Result: No embryotoxic effects., No teratogenic effects.

Test Type: Fertility/early embryonic development  
Species: Mouse  
Application Route: Ingestion  
General Toxicity Maternal: LOAEL: 25 mg/kg body weight  
Result: Maternal toxicity observed., Fetal effects.

Test Type: Fertility/early embryonic development  
Species: Rabbit  
Application Route: Ingestion  
General Toxicity Maternal: LOAEL: <= 12 mg/kg body weight  
Developmental Toxicity: LOAEL: 12.5 mg/kg body weight  
Result: Maternal toxicity observed., Reduced number of viable fetuses.

Test Type: Fertility/early embryonic development  
Species: Rabbit  
Application Route: Ingestion  
General Toxicity Maternal: LOAEL: 15 mg/kg body weight



# SAFETY DATA SHEET

according to the Hazardous Products Regulations



## Furosemide Injection Formulation

|         |                |              |                                 |
|---------|----------------|--------------|---------------------------------|
| Version | Revision Date: | SDS Number:  | Date of last issue: 04/04/2023  |
| 3.9     | 09/30/2023     | 632199-00016 | Date of first issue: 05/03/2016 |

Result: Maternal toxicity observed., No effects on fetal development.

### STOT-single exposure

Not classified based on available information.

### STOT-repeated exposure

Causes damage to organs (Kidney, Liver) through prolonged or repeated exposure.

#### Components:

##### Furosemide:

|                    |  |
|--------------------|--|
| Routes of exposure | : Ingestion  |
| Target Organs      | : Kidney   |
| Assessment         | : Shown to produce significant health effects in animals at concentrations of 10 mg/kg bw or less. |

### Repeated dose toxicity

#### Components:

##### Furosemide:

|                   |  |
|-------------------|--|
| Species           | : Dog                                      |
| NOAEL             | : 4 mg/kg                                  |
| LOAEL             | : 8 mg/kg                                  |
| Application Route | : Ingestion                                |
| Exposure time     | : 12 Months                                |
| Target Organs     | : Kidney                                   |
| Symptoms          | : Blood disorders                          |
| Remarks           | : Significant toxicity observed in testing |

### Aspiration toxicity

Not classified based on available information.

### Experience with human exposure

#### Components:

##### Furosemide:

|              |   |
|--------------|---|
| Inhalation   | : Remarks: May be harmful if inhaled.   |
| Skin contact | : Remarks: May irritate skin.   |
| Eye contact  | : Remarks: May cause eye irritation.  |
| Ingestion    | : Symptoms: Kidney disorders, Headache, electrolyte imbalance, dry mouth, hearing loss, Irregular cardiac activity, Gastrointestinal disturbance, hypotension |

## SECTION 12. ECOLOGICAL INFORMATION

### Ecotoxicity

#### Components:

##### Furosemide:

# SAFETY DATA SHEET

according to the Hazardous Products Regulations



## Furosemide Injection Formulation

|         |                |              |                                 |
|---------|----------------|--------------|---------------------------------|
| Version | Revision Date: | SDS Number:  | Date of last issue: 04/04/2023  |
| 3.9     | 09/30/2023     | 632199-00016 | Date of first issue: 05/03/2016 |

Toxicity to fish : LC50 : 500 mg/l  
Exposure time: 96 h

### Persistence and degradability

No data available

### Bioaccumulative potential

### Components:

#### Furosemide:

Partition coefficient: n-octanol/water : log Pow: 2.03

#### Mobility in soil

No data available

#### Other adverse effects

No data available

## SECTION 13. DISPOSAL CONSIDERATIONS

### Disposal methods

Waste from residues : Do not dispose of waste into sewer.  
Dispose of in accordance with local regulations.  
Contaminated packaging : Empty containers should be taken to an approved waste handling site for recycling or disposal.  
If not otherwise specified: Dispose of as unused product.

## SECTION 14. TRANSPORT INFORMATION

### International Regulations

#### UNRTDG

Not regulated as a dangerous good

#### IATA-DGR

Not regulated as a dangerous good

#### IMDG-Code

Not regulated as a dangerous good

### Transport in bulk according to Annex II of MARPOL 73/78 and the IBC Code

Not applicable for product as supplied.

### Domestic regulation

#### TDG

Not regulated as a dangerous good

### Special precautions for user

Not applicable

# SAFETY DATA SHEET

according to the Hazardous Products Regulations



## Furosemide Injection Formulation

|         |                |              |                                 |
|---------|----------------|--------------|---------------------------------|
| Version | Revision Date: | SDS Number:  | Date of last issue: 04/04/2023  |
| 3.9     | 09/30/2023     | 632199-00016 | Date of first issue: 05/03/2016 |

### SECTION 15. REGULATORY INFORMATION

**The ingredients of this product are reported in the following inventories:**

|       |   |                |
|-------|---|----------------|
| AICS  | : | not determined |
| DSL   | : | not determined |
| IECSC | : | not determined |

### SECTION 16. OTHER INFORMATION

#### Full text of other abbreviations

AIIC - Australian Inventory of Industrial Chemicals; ANTT - National Agency for Transport by Land of Brazil; ASTM - American Society for the Testing of Materials; bw - Body weight; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; ERG - Emergency Response Guide; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; Nch - Chilean Norm; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NOM - Official Mexican Norm; NTP - National Toxicology Program; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; TCSI - Taiwan Chemical Substance Inventory; TDG - Transportation of Dangerous Goods; TECl - Thailand Existing Chemicals Inventory; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative; WHMIS - Workplace Hazardous Materials Information System

Sources of key data used to compile the Material Safety Data Sheet : Internal technical data, data from raw material SDSs, OECD eChem Portal search results and European Chemicals Agency, <http://echa.europa.eu/>

Revision Date : 09/30/2023

# SAFETY DATA SHEET

according to the Hazardous Products Regulations



## Furosemide Injection Formulation

|         |                |              |                                 |
|---------|----------------|--------------|---------------------------------|
| Version | Revision Date: | SDS Number:  | Date of last issue: 04/04/2023  |
| 3.9     | 09/30/2023     | 632199-00016 | Date of first issue: 05/03/2016 |

---

Date format : mm/dd/yyyy

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

CA / Z8